IMPL - Impel Pharmaceuticals Exploring Strategic Alternatives

2023-10-05 09:39:40 ET

DENVER, Colo., Oct 5, 2023 ( www.247marketnews.com )- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) stated, this morning, that it is exploring strategic alternatives and plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of Company assets, a sale of all of the Company, a merger or other strategic transactions. As the Company engaged Moelis & Company to explore strategic options and expects to conduct this process over the remainder of 2023. Impel will continue to provide full commercial support behind Trudhesa, including Trudhesa Direct access support.

Impel Pharmaceuticals is trading at $0.4399, up $0.0289 (+7.03%), on 102.2K premarket shares traded.

Its 52-week range is $0.18 to $2.962. It had a massive …

The post Impel Pharmaceuticals Exploring Strategic Alternatives appeared first on 24/7 Market News .

For further details see: